1. A phase I, first‐in‐human, randomized dose‐escalation study of anti‐activated factor XII monoclonal antibody garadacimab. Issue 3 (3rd December 2021) Authors: McKenzie, Andrew; Roberts, Anthony; Malandkar, Sourabh; Feuersenger, Henrike; Panousis, Con; Pawaskar, Dipti Journal: Clinical and translational science Issue: Volume 15:Issue 3(2022) Page Start: 626 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Exposure‐Response Model of Subcutaneous C1‐Inhibitor Concentrate to Estimate the Risk of Attacks in Patients With Hereditary Angioedema. (9th January 2018) Authors: Zhang, Ying; Tortorici, Michael A.; Pawaskar, Dipti; Pragst, Ingo; Machnig, Thomas; Hutmacher, Matthew; Zuraw, Bruce; Cicardi, Marco; Craig, Timothy; Longhurst, Hilary; Sidhu, Jagdev Journal: CPT: pharmacometrics & systems pharmacology Issue: Volume 7:Number 3(2018) Page Start: 158 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Pharmacokinetic/pharmacodynamic modeling for dose selection for the first‐in‐human trial of the activated Factor XII inhibitor garadacimab (CSL312). Issue 3 (8th December 2021) Authors: Pawaskar, Dipti; Chen, Xi; Glassman, Fiona; May, Frauke; Roberts, Anthony; Biondo, Mark; McKenzie, Andrew; Nolte, Marc W.; Jusko, William J.; Tortorici, Michael Journal: Clinical and translational science Issue: Volume 15:Issue 3(2022) Page Start: 709 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Population pharmacokinetics of subcutaneous C1‐inhibitor for prevention of attacks in patients with hereditary angioedema. Issue 10 (26th August 2018) Authors: Pawaskar, Dipti; Tortorici, Michael A.; Zuraw, Bruce; Craig, Timothy; Cicardi, Marco; Longhurst, Hilary; Li, H. Henry; Lumry, William R.; Martinez‐Saguer, Inmaculada; Jacobs, Joshua; Bernstein, Jonathan A.; Riedl, Marc A.; Katelaris, Constance H.; Keith, Paul K.; Feussner, Annette; Sidhu, Jagdev Journal: Clinical & experimental allergy Issue: Volume 48:Issue 10(2018) Page Start: 1325 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 10328 (5th March 2022) Authors: Craig, Timothy; Magerl, Markus; Levy, Donald S; Reshef, Avner; Lumry, William R; Martinez-Saguer, Inmaculada; Jacobs, Joshua S; Yang, William H; Ritchie, Bruce; Aygören-Pürsün, Emel; Keith, Paul K; Busse, Paula; Feuersenger, Henrike; Pawaskar, Dipti; Jacobs, Iris; Pragst, Ingo; Doyle, Mittie K Journal: Lancet Issue: Volume 399:Issue 10328(2022) Page Start: 945 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗